MedTrace Logo

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

NCT06577935 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 379

Last updated 2026-02-10

No results posted yet for this study

Summary

The primary objective of this study is to determine the effect of treatment with AGA2118 versus placebo at Month 12 on lumbar spine bone mineral density (BMD) in postmenopausal women with low bone mass.

Conditions

  • Postmenopausal Osteoporosis

Interventions

DRUG

AGA2118

Subcutaneous injection

OTHER

Placebo

Subcutaneous injection

Sponsors & Collaborators

  • Angitia Biopharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ricardo Dent-Acosta, MD · Angitia Incorporated Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2026-12-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Poland
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577935 on ClinicalTrials.gov